We don’t follow footsteps.
We create the path.

News & events

World Hemophilia Day 2017
Philadelphia is “Lighting It Up Red” in support of the global bleeding disorders community

Read More read more

HTRS 2017 Scientific Symposium
Spark Therapeutics presents updated preliminary data from hemophilia B Phase 1/2 trial

Read More read more

BIO CEO 2017
Spark CEO Jeff Marrazzo creates a buzz at the BIO CEO & Investor Conference

Read More read more

ID YOUR IRD
Genetic testing now available to eligible patients with certain IRDs through the new Spark initiative, ID YOUR IRD

Read More read more

We don’t follow footsteps. We create the path.

Our mission at Spark Therapeutics is to challenge the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable—until now. We have built a fully integrated company, combining our proprietary adeno-associated viral (AAV) gene therapy platform with excellence in R&D, manufacturing and commercial operations. Find out more about how we strive to turn genes into medicines for patients with inherited diseases, including inherited retinal diseases (IRDs), liver-mediated diseases such as hemophilia, and neurodegenerative diseases.

Learn More